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ABSTRACT 34 
Purpose: Uveal melanoma is the most common primary intraocular malignancy in adults. Iris melanoma 35 
comprises 4-10% of all uveal melanomas and have a lower mortality rate. The genetic changes in iris 36 
melanoma are not as well characterized as ciliary body or choroidal melanoma. The aim of this study was 37 
to gain more insight into the genetic background of iris melanoma and iris nevi. 38 
Design: Multicenter, retrospective case series. 39 
Participants: Patients diagnosed with iris melanoma or iris nevi who underwent surgical intervention as 40 
primary or secondary treatment.  41 
Methods: Next-generation sequencing  of GNAQ, GNA11, EIF1AX, SF3B1, BAP1, NRAS, BRAF, PTEN, 42 
c-Kit, TP53 and TERT was performed on thirty iris melanomas and seven iris nevi. Copy number status 43 
was detected using single nucleotide polymorphisms (613¶V) included in the NGS panel, SNP-array 44 
and/or FISH. BAP1 immunohistochemistry was performed on all samples. 45 
Main Outcome Measures: Mutation and copy number status were analyzed. Results of BAP1 46 
immunohistochemistry were used for survival analysis.  47 
Results: In 26 of the 30 iris melanoma and all iris nevi at least one mutation was identified. Multiple 48 
mutations were detected in 23 iris melanoma and 5 nevi as well as mutations in GNAQ and GNA11. 49 
Furthermore, 13/30 BAP1, 5/30 EIF1AX and 2/30 SF3B1 mutations were identified in iris melanoma. No 50 
correlation between BAP1 status and disease free survival was found. The iris nevi showed one EIF1AX 51 
and three BAP1 mutations. Two of the nevi, with a BAP1 mutation, were histologically µborderline 52 
malignant¶. Mutations in NRAS, BRAF, PTEN, c-KIT and TP53 were detected in six iris melanomas and 53 
four iris nevi.  54 
Conclusions: Mutations that are often found in uveal and cutaneous melanoma were identified in this 55 
cohort of iris melanomas and iris nevi. Therefore, iris melanomas harbor a molecular profile comparable 56 
to both choroidal melanoma and cutaneous melanoma. These findings may offer adjuvant targeted 57 
therapies for iris melanoma. There was no prognostic significance of BAP1 expression as seen in 58 
choroidal melanoma. Consequently, iris melanoma is a distinct molecular subgroup of uveal melanoma. 59 
+LVWRORJLFDOO µERUGHUOLQH PDOLJQDQW¶ LULV QHYL FDQ KDUERU %$3 PXWDWLRQV DQG PD\ EH GHVLJQDWHG ,ULV60 
Melanocytic Tumors of Uncertain Malignant Potential (IMTUMP). 61 
62 
INTRODUCTION 63 
Uveal melanoma is the most common primary intraocular malignancy in adults with an incidence of 64 
7:1.000.000 people in the Western World.1 Iris melanomas comprise 4-10% of all UM.1-4 The observed 65 
and relative survival is higher compared to UM in general.5 There is no difference in incidence between 66 
men and women but they occur more often in the Caucasian population.4, 6 Treatment includes surgical 67 
resection, enucleation, brachytherapy and proton beam irradiation.7, 8 Currently no studies on targeted 68 
adjuvant therapies in primary or metastatic iris melanoma exist. The choice of treatment depends on 69 
tumor size, localization and patient preference. Diffuse iris melanomas are difficult to recognize causing a 70 
delay in diagnosis. Moreover, they have a greater risk of metastasis than nodular iris melanoma.9, 10 Other 71 
clinical risk factors for metastasis include elevated intraocular pressure, iris root or angle involvement, 72 
increased tumor thickness, older patient age and extraocular tumor extension. The metastatic rate of iris 73 
melanoma is quoted as 1-10% at 5 years, 2-10% at 10 years and 10% at 20 years of follow up.6, 10 A 74 
metastatic rate of 11% at 5-years was described in a series of biopsied iris melanoma.11 However, gene 75 
expression profiling of iris melanoma showed that 67% of iris melanoma exhibit a class I (low metastatic 76 
risk) gene expression profile and 33% a class II profile (high metastatic risk).12 77 
Chromosomal abnormalities of iris melanoma are poorly characterized. Partial or complete loss of 78 
chromosome 3 was found in 41-45% and 15-29% respectively.7, 13, 14 Monosomy 3 was correlated with 79 
LQFUHDVLQJSDWLHQWV¶DJH.13 While chromosome 3 loss is described in uveal melanoma as a risk factor for 80 
metastatic disease,15 in iris melanoma this was only associated with a progressive disease in a univariate 81 
analysis. Chromosome 9p loss was reported in 35%.7 Furthermore, loss of 1p and 6q, and gain of 6p, 8 82 
and 8q was described.7, 14 Also abnormalities of chromosomes 5 and 18 have been reported.16  83 
Mutations in genes encoding the guanine nucleotide-binding protein G subunit alpha q and 11 (GNAQ 84 
and GNA11) and the genes BAP1, SF3B1 and EIF1AX are typical for uveal melanoma.17, 18 GNAQ 85 
mutations are more common in ciliary body and choroid UM compared to iris melanoma.19 The aim of this 86 
study was to elucidate the genetic background of iris melanoma and iris nevi and to ascertain whether iris 87 
melanoma constitutes a distinct molecular group amongst uveal melanoma. Next-generation sequencing 88 
(NGS) and immunohistochemistry was used to identify mutations in genes that are involved in both uveal 89 
as well as cutaneous melanoma.  90 
MATERIALS AND METHODS 91 
Inclusion  92 
Tissue was collected from patients with iris melanoma or iris nevi from The Royal Hallamshire Hospital 93 
(Sheffield, UK) and the Rotterdam Ocular Melanoma Studygroup (ROMS) database. The ROMS is 94 
collaboration between the Erasmus MC (Rotterdam, The Netherlands) and The Rotterdam Eye Hospital 95 
(Rotterdam, The Netherlands). Patients with an iris melanoma or suspect iris nevi who underwent biopsy 96 
or enucleation between 1992 and 2016 were included. The study conformed to the tenets of the 97 
Declaration of Helsinki and was approved by the respective local ethics committees. Informed consent 98 
was obtained prior to treatment. All samples were reviewed by one of two ophthalmic pathologists (HM 99 
and RV) to ensure that all tumors were primary iris lesions. Patient charts were reviewed to ascertain 100 
diagnosis as primary iris melanoma, clinical and follow up data.  101 
Immunohistochemistry 102 
Immunohistochemical staining was performed with a BAP1-antibody (clone sc-28383, 1:50 dilution, Santa 103 
Cruz Biotechnology, Dallas, Texas, USA) on 4um sections of formalin fixed paraffin embedded tissue 104 
(FFPE). An automated staining system (VENTANA BenchMark ULTRA, Ventana Medical Systems, 105 
Tuscon, Arizona, USA) was used following the protocol as described previously.20 Only nuclear 106 
expression was scored since nuclear expression is prognostic relevant in uveal melanoma.20, 21 Loss of 107 
expression was defined as absent BAP1 expression in the nucleus. 108 
DNA isolation 109 
DNA was extracted from fresh and FFPE tumor tissue. DNA isolation from fresh material was performed 110 
XVLQJWKH4,$PS'1$PLQLNLW 4LDJHQ+LOGHQ*HUPDQ\DFFRUGLQJWRWKHPDQXIDFWXUHU¶V LQVWUXFWLRQV111 
DNA extracted from FFPE tissue was performed using lysisbuffer (Promega, Madison, Wisconsin, USA) 112 
and 5% Chelex (Bio-Rad, Hercules, California, USA) following the protocol as described before. (Smit KN, 113 
Combined mutation and CNV detection by targeted next-generation sequencing in uveal 114 
melanoma,Modern Pathology, in press). Tumor tissue was confirmed with flanking H&E-slides. DNA 115 
samples were stored at -20°C. 116 
Targeted next-generation sequencing 117 
Targeted NGS was performed using the Ion Personal Genome Machine (PGM) and the Torrent Server 118 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA) according to the PDQXIDFWXUHUV¶ protocol. A 119 
panel including amplicons covering GNAQ, GNA11, BAP1, SF3B1 and EIF1AX was used. Moreover, 120 
NRAS, BRAF, PTEN, c-Kit, TP53 and TERT, genes that harbor mutations in cutaneous melanoma, were 121 
included. On chromosome 1, 3 and 8, amplicons that cover highly polymorphic regions were used to 122 
identify allelic imbalances (Smit KN, van Poppelen NM, Vaarwater J et al. Combined mutation and CNV 123 
detection by targeted next-generation sequencing in uveal melanoma, manuscript submitted). 124 
Mutation analysis 125 
Results from Ion Torrent next-generation sequencing were analyzed using Torrent Suite Software Version 126 
4.4.3 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and Integrative Genomics Viewer (IGV) 127 
Version 2.3.68 (97) (Broad Institute, Cambridge, Massachusetts, USA). All data was manually analyzed 128 
using IGV for the selected ten genes by two individuals. Mutations that occurred in more than 20% of the 129 
reads and with a minimal read count of 50 reads, were called. When there was a low DNA concentration 130 
or when one of the hotspot mutations was present in less than 20% of the total read count, mutations with 131 
a percentage between 10-20% were called. Intronic, non-coding regions and synonymous mutations were 132 
excluded. These results were compared with the mutations from the Variant Call Format (VCF) files. 133 
Mutations were validated using Sanger sequencing following a standardized protocol for FFPE material if 134 
material was available.  135 
Copy number variation 136 
Allelic imbalances were detected using the highly polymorphic regions on chromosome 3. This data was 137 
used to estimate the copy number variation. Furthermore, Nexus Copy Number software (BioDiscovery 138 
Incorporated, El Segundo, California, USA) was used to display copy number variations. Additional single 139 
nucleotide polymorphism (SNP) array and/or fluorescence in situ hybridization (FISH) data was used 140 
when available. SNP-array and FISH results were obtained as described before.22, 23 If there was loss of 141 
chromosome 3p, this was defined as loss of chromosome 3. 142 
Statistical analysis 143 
For statistical analysis IBM SPSS Statistics Version 21 (SPSS for Windows, International Business 144 
Machines Corporation (IBM), North Castle, New York, USA) was used. Kaplan-Meier analysis with log 145 
rank test was used for survival analysis. A P-value <0.05 was considered significant.  146 
RESULTS 147 
Patient characteristics 148 
Iris melanomas 149 
Between 1992 and 2016, from 31 patients that were treated for iris melanoma at Erasmus MC, The 150 
Rotterdam Eye Hospital and by the Ocular Oncology Service at the Royal Hallamshire Hospital, tissue 151 
material was available. From the Royal Hallamshire Hospital Sheffield 20 patients were included and 11 152 
patients from the Erasmus MC and The Rotterdam Eye Hospital. One patient who developed liver 153 
metastasis after 34.3 months was excluded because of low tumor DNA concentrations, which made 154 
genetic analysis unreliable. There were 17 males (57%) and 13 females (43%) with a mean age at 155 
diagnosis of 47.1 years (range from 16.7 to 70.4 years). Fourteen patients were treated with 156 
iridocyclectomy (47%). All ten patients from Erasmus MC and The Rotterdam Eye Hospital and one 157 
patient from the Royal Hallamshire Hospital underwent enucleation (37%). Three patients were treated 158 
with local iris resection (10%), one with iridectomy (3%) and one with proton beam therapy (3%). This 159 
latter patient was treated with cryotherapy for raised intraocular pressure 47.8 months after primary 160 
treatment, followed by enucleation because of a blind painful eye.  161 
Two patients (7%) received additional treatment with ruthenium plaque and proton beam therapy because 162 
of incomplete excision of iris melanoma. One patient received additional treatment (stereotactic 163 
radiotherapy) although the resection was histologically complete. In two patients (7%) recurrent iris 164 
melanoma developed after 28.6 and 15.5 months after the primary treatment, necessitating proton beam 165 
therapy and enucleation respectively. In one patient, 37.0 months after additional treatment, diffuse 166 
recurrent iris melanoma with raised intra ocular pressure developed and the eye was enucleated.  167 
Three patients (10%) underwent trabeculectomy because of glaucoma, (five, five and eleven years) prior 168 
to the diagnosis of iris melanoma. Two patients were clinically diagnosed to have an iris nevus at the time 169 
of trabeculectomy. In the third patient, pigment was seen preoperative. Biopsy of the iris four years later 170 
revealed a borderline malignant nevus and iris melanoma was diagnosed after seven years. In this 171 
patient, metastatic disease developed 21.3 months after primary treatment of iris melanoma. The other 172 
two patients who underwent trabeculectomy did not develop metastatic disease. One patient was 173 
clinically diagnosed with a nevus and receive a Baerveldt Glaucoma Implant (BGI) because of glaucoma 174 
almost 1.5 year before the diagnosis iris melanoma was made. Because of the iris melanoma diagnosis, 175 
the BGI was surgically closed and the eye was enucleated three weeks later. See Table 1 for an overview 176 
of patient characteristics. 177 
The mean disease free survival (DFS) was 114.5 months with a range from 13.8 to 239.3 months. 178 
Metastasis in the liver developed in two patients (7%) after 21.3 and 31.9 months. Kapan Meier analysis 179 
showed no significant difference in disease free survival between patients with a BAP1 positive tumor 180 
compared to a BAP1 negative tumor (P = 0.470), (Figure 1).   181 
Iris nevi 182 
The seven patients with iris nevi from the ROMS-database comprised five females (42%) and two males 183 
(29%) with a mean age at diagnosis of 58.5 years (range 0.2 ± 78.3 years). One patient underwent 184 
enucleation (14%), in three patients the nevi was excised in toto (43%) and three were biopsied (43%). 185 
None of these patients developed metastasis during follow-up (35.8-64.7 months). Six nevi were 186 
histologically classified as µborderline malignant¶ according to the Jakobiec and Silbert classification.24   187 
Genetic analysis 188 
Ion Torrent data (Thermo Fisher Scientific, Waltham, Massachusetts, USA) was analyzed for GNAQ, 189 
GNA11, BAP1, SF3B1, EIF1AX, NRAS, BRAF, PTEN, C-KIT, TP53 and TERT promoter mutations. TERT 190 
promoter results were excluded for further analysis due to a read count lower than fifty. An overview of 191 
the results is displayed in Figure 2. A GNAQ mutation was found in 15 iris melanomas (50.0%) in which 192 
11 tumors harbored a c.626A>T:p.Gln209Leu mutation (37%), two a c.626A>C:p.Gln209Pro mutation 193 
(7%), one a c.548G>A:pArg183Gln (3%) and one both a c.619G>A:pGly207Arg as well as a 194 
c.620G>A:p.Gly207Glu mutation (3%). GNA11 was mutated in nine iris melanomas (30%) which 195 
consisted of six c.626A>T:p.Gln209Leu (20%) and three c.547C>T:p.Arg183Cys mutations (10%). An 196 
EIF1AX mutation was identified in five tumors (17%); three c.5_6TT:p.Pro2Leu mutations (10%), one 197 
c.22G>A:p.Gly8Arg mutation (3%) and one c.44G>A:pGly15Asp mutation (3%). A 198 
c.1873C>T:p.Arg625Cys mutation in SF3B1 was seen in one iris melanoma (3%) and a 199 
c.1858A>G:p.Met620Val mutation in another tumor (3%). One or more BAP1 mutations were found in 13 200 
iris melanomas (43%).  201 
For three iris melanomas no mutation status of NRAS, BRAF, PTEN, c-KIT and TP53 was available. A 202 
TP53 mutation was detected in four (13%), a NRAS mutation in three (10%), a PTEN mutation in three 203 
(10%), a c-KIT mutation in two (7%) and a c.1781A>G:p.D594G BRAF mutation in one iris melanoma 204 
(3%). The exact mutations are described in Supplementary Information, Table S1 (available at 205 
www.aaojournal.org). Four iris melanomas did not have a mutation in any of the tested genes, BAP1 IHC 206 
was positive for all four of these samples.  207 
In the iris nevi (n=7), four GNAQ c.626A>T:p.Gln209Leu mutations (57%) and one GNA11 208 
c.626A>T:p.Gln209Leu (14%) were found. Three nevi, of which two borderline malignant, harbored one 209 
or more BAP1 mutations (43%), one an EIF1AX c.16G>A:pGly6Ser mutation (14%). Mutations in NRAS 210 
were found in four nevi (57%), c-KIT in three (43%), PTEN in one (14%) and TP53 in one nevus (14%). 211 
An overview of the mutations in iris melanoma and nevi are shown in Figure 2. See supplementary 212 
information Table S1 for a detailed overview of the mutations that were detected.  213 
Reliable Sanger sequencing results were obtained from three patients with a mutation in PTEN, BRAF 214 
and NRAS. The mutations in BRAF and PTEN were confirmed. Surprisingly, besides the known PTEN 215 
mutation, another mutation in PTEN was detected with Sanger sequencing, a. c.703G>A:p.Glu235Lys 216 
mutation.  217 
Immunohistochemistry 218 
Immunohistochemical staining for BAP1 was performed on all iris melanoma and iris nevus sections. 219 
None of the iris nevi showed loss of BAP1 expression (Figure 3) BAP1 expression was positive in 21 iris 220 
melanoma samples (70%) and negative in 9 samples (30%). Six iris melanomas showed no BAP1 221 
expression in >90% of the tumor cells, in two cases loss of BAP1 expression was observed in 80% and 222 
50% of the tumor cells, respectively. In the remaining BAP1 negative iris melanoma, part of the tumor 223 
(40%) consisted of epithelioid cells which lacked BAP1 expression and whereas the spindle tumor cells 224 
did show BAP1 expression, see Figure 4.  225 
Copy number status 226 
Copy number loss of chromosome 3 was detected in 13 samples consisting of 12 iris melanoma and one 227 
borderline nevus. SNP-array data was available for four samples and FISH was performed in ten 228 
VDPSOHV7KHUHVXOWVIURPFRS\QXPEHUGHWHFWLRQXVLQJWKH613¶VIURPWKH1*6SDQHO613-array and 229 
FISH were consistent whenever more than one technique was available for analysis. The copy number 230 
status of cases 21-29 and 31 were evaluated by more than one technique. An overview of the copy 231 
number status, BAP1 IHC and BAP1 mutations is given in Figure 2 .  232 
DISCUSSION  233 
To our knowledge, this is the largest study of genetic mutation analysis in iris melanoma and iris nevi for 234 
genes that are involved in either uveal or cutaneous melanoma. Iris melanoma and nevi harbor mutations 235 
that are found in primary choroidal and cutaneous melanoma. In UM, prognosis is related to nuclear 236 
BAP1 expression20, 21 while in this study, no significant association was found between nuclear BAP1 237 
expression and disease free survival in iris melanoma. Knowledge of the molecular profile is fundamental 238 
since potential therapies targeting the cutaneous melanoma signature could have clinical implications in 239 
iris melanoma.   240 
Thirty iris melanomas and seven iris nevi were analyzed for mutations in GNAQ, GNA11, EIF1AX, 241 
SF3B1, BAP1, NRAS, BRAF, PTEN, c-KIT and TP53 using NGS and BAP1 immunohistochemistry. In 242 
this cohort, more GNAQ mutations were detected compared to GNA11 mutations, which is in line with 243 
previous reported mutations in iris melanoma.25 A hotspot GNAQ or GNA11 mutation was found in 23 244 
(77%) iris melanomas and five iris nevi (72%). These mutations are the same hotspot mutations as 245 
described in uveal melanoma. However, the mutation rate is lower compared to uveal melanoma in which 246 
a rate up to 93% is described.18 Other genes that have been described in 3.0-7% of uveal melanoma 247 
involving the GĮs activating or GĮi inhibitory adenylyl cyclase pathway, such as CYSLTR2 and PLCB4,26, 27 248 
could be involved in iris melanoma as well. It would be interesting to investigate whether CYSLTR2 and 249 
PLCB4 are mutated in iris melanoma with a GNAQ or GNA11 wildtype profile, although no mutations in 250 
CYSLTR2 have been found in an earlier study of nineteen iris melanomas.21 GNAQ and GNA11 251 
upregulate the mitogen-activated protein kinase (MAPK) pathway as well as activating BRAF and NRAS 252 
mutations.28 However, the mutation in BRAF (D594G) in our cohort did co-exist with a GNA11 mutation. 253 
Mutations in BRAF have been described previous in 9/19 iris melanomas, but these mutations were 254 
located at a different position than in our cohort.29  255 
NRAS mutations were detected both with and without mutations in GNAQ and GNA11. Inhibition of MEK, 256 
a kinase in the mitogen-activated protein kinase (MAPK), is an accepted treatment in specific metastatic 257 
cutaneous melanoma cases.30, 31 In contrast, response rates are lower in patients with metastatic uveal 258 
melanoma.31 Since iris melanomas harbor mutations in genes that are present in cutaneous melanoma 259 
as well, unlike uveal melanoma, a study to elucidate the effect of MEK-inhibitors in this specific patient 260 
group may be warranted.   261 
Mutations in SF3B1 and EIF1AX were detected in 7% and 17% cases respectively. Considering the 262 
sample size, this is comparable to uveal melanoma in which mutations in SF3B1 vary between 10% to 263 
24% and EIF1AX mutated tumors are reported around 20%.32, 33 A recent study of 19 iris melanomas 264 
showed mutations in EIF1AX, but no mutations in SF3B1, BRAF, NRAS and c-KIT.25 However, mutations 265 
in NRAS, BRAF, PTEN, c-KIT and TP53 were found in both iris melanoma and nevi in our series. In The 266 
Cancer Genome Atlas, only one deletion in c-KIT has been described before. This supports our 267 
hypothesis that iris melanoma should be treated as a distinct subgroup of uveal melanoma. An extra 268 
mutation in 50% of the alleles of PTEN was detected at confirmation testing with Sanger sequencing. 269 
Possibly, only one allele was covered with NGS so that this mutation was not detected. In four iris 270 
melanoma no mutations were detected which supports our hypothesis of iris melanoma as a distinct 271 
subgroup. Possibly, other driver genes are involved in the development of iris melanoma. These samples 272 
are subject for additional investigations. 273 
Some studies suggest that mutations in uveal and iris melanoma might be associated with ultraviolet 274 
exposure.25, 34 However, in a whole-genome sequencing study of uveal melanoma, no UV-induced 275 
mutation signature was found.35 In the current study, it is doubtful whether the mutations that we identified 276 
in NRAS, BRAF, PTEN, c-KIT and TP53 are related to ultraviolet light exposure since the primary tumors 277 
were located in different quadrants of the eye. Furthermore, the mutations that were found in the 278 
cutaneous melanoma associated genes were not predominantly C>T or CC>TT mutations, which are 279 
known to be caused by ultraviolet light damage.36 Neither relations between the mutations and 280 
geographical differences or regional effects could be observed. Future studies are needed to validate the 281 
prevalence of mutations in NRAS, BRAF, PTEN, c-KIT and TP53 and their clinical relevance in iris 282 
melanoma.  283 
It is known that chromosome 3 loss is correlated with BAP1 mutations in uveal melanoma.17 Therefore, 284 
copy number status was compared to BAP1 mutations detected with NGS and BAP1 IHC. Loss of 285 
chromosome 3 was detected in 13 samples, including one iris nevus. Chromosome 3 loss is described in 286 
iris melanoma as well as abnormalities in chromosome 1, 5, 6, 8, 9 and 18.7, 16 Loss of expression of 287 
BAP1 using immunohistochemistry is described in 43% to 50% of uveal melanomas20, 37 and in 1/3 iris 288 
melanomas.25 In our study immunohistochemistry for BAP1 was negative in 30% of iris melanomas but a 289 
BAP1 mutation was found in 43% using Ion Torrent next generation sequencing (Thermo Fisher 290 
Scientific, Waltham, Massachusetts, USA). In four tumors with BAP1 expression, a mutation was detected 291 
with the sequencing results. Two of these iris melanomas had two copies of chromosome 3 which means 292 
that the wildtype allele can produce the BAP1 protein. For the other two cases with monosomy 3, it is 293 
possible that the mRNA is not degraded by nonsense-mediated mRNA decay. Probably, a non-functional 294 
BAP1 protein is expressed in these tumors. In all tumors with loss of BAP1 expression, mutations were 295 
detected with NGS.  296 
In general, iris melanomas have a favorable prognosis compared to posterior uveal melanoma.5 BAP1 297 
mutations and chromosome 3 loss are correlated with a poor prognosis in posterior uveal melanoma.15, 20 298 
Metastatic disease to the liver developed in two patients with iris melanoma (6.7%), one of them 299 
underwent trabeculectomy prior to the diagnosis. Both tumors harbored a BAP1 mutation and had no 300 
BAP1 expression in the tumor cells. Nevertheless, this study demonstrates that there is no relation 301 
between BAP1 and prognostic outcome in iris melanoma (Figure 1). Therefore, the prognostic value of 302 
chromosome 3 and BAP1 status for iris melanoma is equivocal. 303 
In the iris nevi, mutations in GNAQ and GNA11 were identified. This is in line with the concept that 304 
mutations in these genes are an early event in tumorigenesis.18 Moreover, a GNAQ mutation in an iris 305 
nevus is described before.25 Interestingly, mutations in BAP1 were detected in three nevi, two of which 306 
were classified histologically as µborderline malignant¶ prior to knowing the BAP1 status. One of these 307 
µborderline malignant¶ nevi was from an enucleated eye and the other two were excised because they 308 
were also clinically suspect. Since these µborderline malignant¶ nevi were completely removed, it is 309 
uncertain if they would have developed into iris melanoma. Because most nevi showed borderline 310 
characteristics, the mutation status of typical nevi might be different. All µborderline malignant¶ iris nevi 311 
showed retained BAP1 expression. It is possible that the BAP1 expressing nevus cells obscured the 312 
small number of malignant subclones to confidently identify loss of BAP1 expression in these lesions. 313 
Further single cell analysis is warranted to resolve this issue. In case of a heterozygous mutation, the 314 
other allele can produce BAP1. 315 
To conclude, our study identified mutations in GNAQ, GNA11, BAP1, SF3B1, EIF1AX, BRAF, PTEN, c-316 
KIT and TP53 in iris melanoma and iris nevi. These mutations were found in a cohort composed of 317 
samples from different institutes, with an even distribution. µBorderline malignant¶ iris nevi harbor 318 
mutations that confirm their clinical and histopathological borderline malignant status. We think it would 319 
be better to designate such cases as iris melanocytic tumors of uncertain malignant potential (IMTUMP), 320 
in line with the terminology used for uncertain cutaneous melanocytic lesions (e.g. MelTUMP-melanocytic 321 
tumor of uncertain malignant potential).38 This would be justified on a combination of histological and 322 
molecular findings presented in this study. Since BRAF, PTEN, c-KIT and TP53 mutations are not typical 323 
for uveal melanoma, iris melanoma and iris nevi should be considered a distinct subgroup, based not only 324 
on clinical and histopathological criteria, but also on molecular grounds.  325 
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  415 
Legends figures 416 
Figure 1. Kaplan-Meier curve showing disease-free survival for iris melanoma with a positive BAP1 417 
expression compared to iris melanoma with a BAP1 negative expression. There is no significant 418 
difference between the two groups (P > 0.05).  419 
Figure 2. Overview of mutations, copy number variation and BAP1 immunohistochemistry in all iris 420 
melanomas. The numbers represents all iris melanoma and nevi samples. In the first row the known uveal 421 
melanoma hotspot mutations in GNAQ and GNA11 detected with next-generation sequencing are 422 
displayed. The second and third row represents mutations that were identified with next-generation 423 
sequencing in GNAQ, GNA11, BAP1, SF3B1, EIF1AX, NRAS, BRAF, PTEN, c-KIT, and TP53. The fourth 424 
URZ LQGLFDWHV WKH FRS\ QXPEHU YDULDWLRQ RI FKURPRVRPH  GHWHFWHG ZLWK 613¶s included in the next-425 
generation sequencing panel, fluorescent in situ hybridization and/or SNP-array data. The fifth row 426 
represents BAP1 expression using immunohistochemistry.  427 
Abbreviations: CNV = copy number variation; IHC = immunohistochemistry. 428 
* MetDVWDVL]LQJWXPRUVERUGHUOLQHPDOLJQDQW 429 
Figure 3. Histopathological features of two iris nevi. A and B are the same nevus as well as C and D. Left 430 
nevus: monosomy 3, no BAP1 mutation was detected. Right nevus: disomy 3, a c.2146G>A mutation in 431 
BAP1 was identified. A, Haematoxylin and eosin (H&E) staining of an iris nevi (400x). B, H&E staining of 432 
an iris nevi (400x). This is an Iris Melanocytic Tumor of Uncertain Malignant Potential (IMTUMP). C, BAP1 433 
staining of an iris nevus, there is nuclear expression (400x). D, Positive nuclear BAP1 expression in an 434 
borderline malignant iris nevus (400x).  435 
Figure 4. Histopathological features and next-generation sequencing (NGS) results displayed in 436 
Integrative Genomics Viewer (IGV) of three iris melanoma samples. A, Haematoxylin and eosin (H&E) 437 
staining (200x) . B, H&E-staining of mixed spindle and epitheliod tumor cells (100x). C, The tumor shows 438 
mixed spindle and epitheliod cells in a H&E staining (200x). D, Positive nuclear BAP1 439 
immunohistochemical (IHC) expression in the tumor cells (400x). E, IHC revealed no BAP1 expression 440 
(100x) F, Positive BAP1 expression (IHC) in spindle cells, absent BAP1 expression in epitheloid cells 441 
(400x). G, NGS results shows a c.548G>A:p.R183Q mutation in GNAQ. H, BAP1 c.312_319del:p.S104fs 442 
displayed in IGV I, Mutation in BAP1 c.1165C>T:p.R389.  443 
